
Rumbidzayi Zinyuke
Senior Health Reporter
THE National Pharmaceutical Company says it is ready to venture into pharmaceutical manufacturing after recording major gains in stabilising the country’s medicines supply chain in 2025, a shift expected to strengthen national self-reliance and reduce dependence on imports.
NatPharm chief executive officer Mr Newman Madzikwa said improvements achieved during the year had created a platform for the parastatal to move beyond distribution and into local production, following lessons drawn from regional and international benchmarks.
“We believe we are now ready to start embarking on manufacturing projects. That will be a major undertaking for the entity going forward,” Mr Madzikwa said.
The move follows what officials describe as one of NatPharm’s strongest years in addressing long-standing weaknesses in medicine distribution, warehousing and availability across public health institutions.
Mr Madzikwa said while challenges remained, the gains recorded in 2025 demonstrated the parastatal’s growing operational capacity.
“The performance for NatPharm for 2025 has been quite satisfactory, given the plans that we had at the beginning of the year. However, it has also demonstrated to us that we have the capacity to do even better. It is exciting that we were able to move stock that had overstayed in our warehouses to the areas where it was needed and we saw an increase in availability, although not to the levels that we really wanted,” he said.
The turnaround comes as Government, under the National Development Strategy 2 (NDS2), intensifies efforts to end medicine stock-outs while building a resilient, locally supported pharmaceutical system.
A key highlight for NatPharm in 2025 was the commissioning of the Mutare regional warehouse, which emerged as a strategic logistics hub for Manicaland Province and a gateway for medicines entering the country through the Beira Port.
The facility has reduced turnaround times for hospitals and clinics in the eastern region, while strengthening Zimbabwe’s capacity to receive pharmaceutical commodities.
Mr Madzikwa said the warehouse, officially commissioned by President Mnangagwa in October, was central to NatPharm’s long-term logistics strategy.
“The Mutare warehouse gives us increased capacity not only to distribute commodities in Manicaland Province, but also to receive commodities that come through the Beira Port,” he said.
Looking ahead to 2026, NatPharm plans to refurbish its Harare national warehouse into a fully pharma-grade facility, with support from Government and development partners. The upgrade is expected to improve compliance with international storage standards and provide a backbone for future manufacturing operations.
NatPharm has also strengthened its distribution capacity during the year by expanding its trucking fleet and introducing scheduled delivery calendars, bringing greater predictability and reliability to medicine supplies at health institutions.
President Mnangagwa is on record reaffirming the Government’s commitment to capacitating NatPharm to guarantee the steady availability of essential medicines, while accelerating local pharmaceutical production as a pillar of national self-reliance.
“I urge the Ministry of Health and Child Care to ensure that the construction of additional regional warehouses in other provinces goes according to plan. This will significantly improve the operational efficiency in the access to medicines, drugs and medical consumables in our health service delivery system and further enhance our quest to achieve Universal Health Coverage. Going forward, I want to assure the nation that Government will continue to capacitate NatPharm, to ensure the availability of medicines,” the President said at the commissioning of the Mutare Warehouse.
He stressed the need to stimulate productivity through local manufacturing of medicines and medical equipment.
President Mnangagwa also highlighted progress being made in the sector, noting a steady increase in the number of pharmaceutical manufacturing entities.
“It is praiseworthy that since 2018, there has been a 56 percent increase in the number of pharmaceutical manufacturing entities from nine in 2020 to the current 14. I, however, challenge Government players together with the private sector, institutions of higher learning, as well as Development Partners to scale up collaboration so that we add on to the current plants,” he added.
From stabilised supply chains and expanded regional warehouses to improved deliveries and medicine availability, the gains recorded in 2025 mark a decisive turning point.
For NatPharm, they are now underpinning a strategic shift towards pharmaceutical manufacturing, a move expected to redefine Zimbabwe’s medicines landscape under NDS2.
The post Self-reliance by design…NatPharm sets sights on drug manufacturing appeared first on herald.
The post Self-reliance by design…NatPharm sets sights on drug manufacturing appeared first on Zimbabwe Situation.



